Holen Sie sich die Stockscreener-App
1.42
34.29%
0.37
Schlusskurs vom Vortag:
$1.05
Offen:
$1.08
24-Stunden-Volumen:
634.83K
Relative Volume:
3.69
Marktkapitalisierung:
$60.16M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.06M
KGV:
-3.9765
EPS:
-0.3571
Netto-Cashflow:
$-1.79M
1W Leistung:
+36.89%
1M Leistung:
+31.78%
6M Leistung:
+0.71%
1J Leistung:
+60.23%
1-Tages-Spanne:
$1.07
$1.45
1-Wochen-Bereich:
$1.01
$1.45
52-Wochen-Spanne:
$0.78
$3.15
Estrella Immunopharma Inc Stock (ESLA) Company Profile
Firmenname
Estrella Immunopharma Inc
Sektor
Branche
Telefon
(510) 318-9098
Adresse
5858 HORTON STREET, SUITE 370, EMERYVILLE
Compare ESLA vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ESLA
Estrella Immunopharma Inc
|
1.41 | 44.80M | 0 | -13.06M | -1.79M | -0.3571 |
VRTX
Vertex Pharmaceuticals Inc
|
433.68 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.51 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.60 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
331.03 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.76 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Estrella Immunopharma Inc Aktie (ESLA) Neueste Nachrichten
ESLA Should I Buy - Intellectia AI
Aug Outlook: Should you buy the dip on Estrella Immunopharma Inc2026 Analyst Calls & Community Consensus Trade Alerts - baoquankhu1.vn
Estrella Immunopharma ESLA US - Smartkarma
Insider Sell: Is Estrella Immunopharma Inc stock technically oversold2026 Fed Impact & Verified Short-Term Plans - baoquankhu1.vn
Silexion Granted Approval to Launch Human Trials That Could Redefine the Future of Cancer Treatment - Benzinga
Top Curanex Pharmaceuticals (CURX) Competitors 2026 - MarketBeat
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research - BioSpace
Masco Corporation Announces Date for Earnings Release and Conference Call for 2026 First Quarter - weeklyvoice.com
If You Invested $1,000 in Estrella Immunopharma (ESLA) - Stock Titan
Estrella Immunopharma, Inc.: Fundamental Analysis and Financial Ratings | ESLA | US2975841048 - MarketScreener
Estrella Immunopharma: Advancing Next-Generation T-Cell Therapies for Cancer and Autoimmune Diseases - Minichart
Estrella 10-K: Net loss widens to $13.1M in 2025; cash $1.4M, working capital deficit $11.9M - TradingView
Tranche Update on Estrella Immunopharma, Inc.'s Equity Buyback Plan announced on January 30, 2024. - marketscreener.com
ESLA PE Ratio & Valuation, Is ESLA Overvalued - Intellectia AI
EB103 lymphoma trial data and pipeline update from Estrella (NASDAQ: ESLA) - Stock Titan
Certain Common Stock of Estrella Immunopharma, Inc. are subject to a Lock-Up Agreement Ending on 8-MAR-2026. - marketscreener.com
Gainers Report: Is Estrella Immunopharma Inc stock a good pick for beginnersJuly 2025 Chart Watch & Intraday High Probability Setup Alerts - baoquankhu1.vn
ESLA Earnings History & Surprises | EPS & Revenue Results | ESTRELLA IMMUNOPHARMA INC (NASDAQ:ESLA) - ChartMill
Volume Summary: Is Estrella Immunopharma Inc currently under institutional pressureJuly 2025 Momentum & Low Volatility Stock Suggestions - baoquankhu1.vn
ESLAW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ESLA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ESLA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
What’s next for Estrella Immunopharma Inc. stockJuly 2025 Decliners & Accurate Entry and Exit Point Alerts - mfd.ru
Travel Stocks: Is Estrella Immunopharma Inc part of any ETFWeekly Investment Recap & Weekly Momentum Picks - baoquankhu1.vn
Will Estrella Immunopharma Inc. benefit from government policyJuly 2025 Trade Ideas & Step-by-Step Swing Trade Plans - mfd.ru
Can Estrella Immunopharma Inc. sustain its profitabilityMarket Trend Summary & Short-Term Trading Opportunity Alerts - mfd.ru
Why Estrella Immunopharma Inc. stock is recommended by analystsMarket Movement Recap & Consistent Income Trade Ideas - mfd.ru
ESLA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Portfolio Update: Will Estrella Immunopharma Inc benefit from government policy2025 Growth vs Value & Accurate Intraday Trade Tips - baoquankhu1.vn
Estrella reports 100% complete response rate in lymphoma trial By Investing.com - Investing.com South Africa
Estrella reports 100% complete response rate in lymphoma trial - Investing.com Nigeria
Merger Talk: Is INFA a strong growth stock2025 Dividend Review & Fast Gain Stock Trading Tips - baoquankhu1.vn
ESLA: 100% CR Rate in Phase 1/2 Trial of EB103 in Aggressive B Cell NHL - Yahoo Finance
D. Boral Capital Reiterates Buy Rating for Estrella Immunopharma (NASDAQ:ESLA) - MarketBeat
Estrella Immunopharma Reports Positive STARLIGHT-1 Trial Results - Intellectia AI
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR® - Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
ESLA Price Today: Estrella Immunopharma, Inc. Stock Price, Quote & Chart - MEXC Exchange
12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT(R) & CIBMTR(R) - marketscreener.com
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR - BioSpace
Estrella to present phase 1 data on CD19-targeted cell therapy - Investing.com Canada
Estrella to present phase 1 data on CD19-targeted cell therapy By Investing.com - Investing.com South Africa
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR® - Yahoo Finance
Market Moves: Does Estrella Immunopharma Inc stock have upside surprise potentialBear Alert & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Market Recap: Should I invest in Marvell Technology Inc before earnings2025 Investor Takeaways & Short-Term Swing Trade Alerts - baoquankhu1.vn
ESLA Analyst Rating: Target Price Cut by 50% to $8 | ESLA Stock News - GuruFocus
Rally Mode: How much upside does Estrella Immunopharma Inc have2025 Risk Factors & High Accuracy Swing Trade Signals - baoquankhu1.vn
How much upside does Estrella Immunopharma Inc have2025 Risk Factors & High Accuracy Swing Trade Signals - baoquankhu1.vn
Is Estrella Immunopharma Inc. stock overvalued or fairly pricedWeekly Stock Report & Daily Volume Surge Signals - bollywoodhelpline.com
Panic Selling: Is Estrella Immunopharma Inc stock a hidden gemWeekly Profit Analysis & Breakout Confirmation Trade Signals - baoquankhu1.vn
Finanzdaten der Estrella Immunopharma Inc-Aktie (ESLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):